Experienced in WT1-Related Wilms Tumor Syndromes

Sebastien A. Anguille

Antwerpen, VLG, BE 
Experienced in WT1-Related Wilms Tumor Syndromes
Antwerpen, VLG, BE 
OverviewLocationsClinical Research

Overview

Sebastien Anguille practices in Antwerpen, Belgium. Mr. Anguille is rated as an Experienced expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Wilms Tumor, Acute Myeloid Leukemia (AML), Metastatic Pleural Tumor, and Leukemia.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of WT1-Related Wilms Tumor Syndromes.

Gender
Male

Locations

Antwerpen, VLG, Belgium
Other Locations
Edegem, VLG, Belgium
Wilrijk, VLG 2610, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter Observational Belgian Study Assessing the Impact of Newly Started Treatment on the QOL in Patients Suffering From Myelodysplastic Syndromes.
A Multicenter Observational Belgian Study Assessing the Impact of Newly Started Treatment on the QOL in Patients Suffering From Myelodysplastic Syndromes.
Enrollment Status: Completed
Publish Date: March 30, 2025
Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2024
Intervention Type: Biological
Study Drug: Autologous WT1 mRNA-Electroporated Dendritic Cell Vaccine
Study Phase: Phase 2
View 1 Less Clinical Trial

79 Total Publications

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.
Journal: Leukemia
Published: June 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Anguille's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile